In vitro we have shown that the PI3K inhibitor copanlisib and the MEK inhibitor refametinib have anti-proliferative effects as monotherapy in some HER2-positive GC cell lines, including those that are intrinsically resistant to trastuzumab. This evidence concerns the gene MAP2K7 and gastric cancer.